Apothecary Pharma recalls compounded tirzepatide vials due to sterility concerns; 3.6 million Little Giant ladders recalled over injury risks
Apothecary Pharma has initiated a recall of compounded tirzepatide vials that were distributed nationwide, citing concerns over sterility. The recall has drawn attention from the…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 7 11:05 ETSource: SSBCrack
From the source
Read at news.ssbcrack.comApothecary Pharma recalls compounded tirzepatide vials due to sterility concerns; 3.6 million Little Giant ladders recalled over injury risks
Apothecary Pharma has initiated a recall of compounded tirzepatide vials that were distributed nationwide, citing concerns over sterility. The recall has drawn attention from the FDA, which has classified it due to the significant risks associated with the compromised sterility of the product. The North Carolina-based company is facing scrutiny regarding its production practices and quality contro
